Literature DB >> 32461361

USP37 promotes deubiquitination of HIF2α in kidney cancer.

Kai Hong1,2, Lianxin Hu3, Xijuan Liu2, Jeremy M Simon2,4,5, Travis S Ptacek2,5, Xingnan Zheng2, Chengheng Liao3, Albert S Baldwin2, Qing Zhang6.   

Abstract

Clear cell renal cell carcinoma (ccRCC) is characterized by loss of tumor suppressor Von Hippel Lindau (VHL) function, which leads to accumulation of hypoxia inducible factor α (including HIF1α and HIF2α). HIF2α was previously reported to be one of the major oncogenic drivers in ccRCC, however, its therapeutic targets remain challenging. Here we performed a deubiquitinase (DUB) complementary DNA (cDNA) library binding screen and discovered that ubiquitin-specific peptidase 37 (USP37) is a DUB that binds HIF2α and promotes HIF2α deubiquitination. As a result, USP37 promotes HIF2α protein stability in an enzymatically dependent manner, and depletion of USP37 leads to HIF2α down-regulation in ccRCC. Functionally, USP37 depletion causes decreased cell proliferation measured by MTS, two-dimensional (2D) colony formation as well as three-dimensional (3D) anchorage- independent growth. USP37 is also essential for maintaining kidney tumorigenesis in an orthotopic xenograft model and its depletion leads to both decreased primary kidney tumorigenesis and spontaneous lung metastasis. Our results suggest that USP37 is a potential therapeutic target in ccRCC.

Entities:  

Keywords:  HIF2α; USP37; ccRCC; deubiquitination

Mesh:

Substances:

Year:  2020        PMID: 32461361      PMCID: PMC7293621          DOI: 10.1073/pnas.2002567117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

Review 1.  Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing.

Authors:  H Yang; W G Kaelin
Journal:  Cell Growth Differ       Date:  2001-09

2.  Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss.

Authors:  Xijuan Liu; Jeremy M Simon; Haibiao Xie; Lianxin Hu; Jun Wang; Giada Zurlo; Cheng Fan; Travis S Ptacek; Laura Herring; Xianming Tan; Mingjie Li; Albert S Baldwin; William Y Kim; Tao Wu; Marc W Kirschner; Kan Gong; Qing Zhang
Journal:  Mol Cell       Date:  2020-02-04       Impact factor: 17.970

3.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

4.  Targeting renal cell carcinoma with a HIF-2 antagonist.

Authors:  Wenfang Chen; Haley Hill; Alana Christie; Min Soo Kim; Eboni Holloman; Andrea Pavia-Jimenez; Farrah Homayoun; Yuanqing Ma; Nirav Patel; Paul Yell; Guiyang Hao; Qurratulain Yousuf; Allison Joyce; Ivan Pedrosa; Heather Geiger; He Zhang; Jenny Chang; Kevin H Gardner; Richard K Bruick; Catherine Reeves; Tae Hyun Hwang; Kevin Courtney; Eugene Frenkel; Xiankai Sun; Naseem Zojwalla; Tai Wong; James P Rizzi; Eli M Wallace; John A Josey; Yang Xie; Xian-Jin Xie; Payal Kapur; Renée M McKay; James Brugarolas
Journal:  Nature       Date:  2016-09-05       Impact factor: 49.962

5.  Mammalian tumor suppressor Int6 specifically targets hypoxia inducible factor 2 alpha for degradation by hypoxia- and pVHL-independent regulation.

Authors:  Li Chen; Kazuyo Uchida; Alexander Endler; Futoshi Shibasaki
Journal:  J Biol Chem       Date:  2007-02-26       Impact factor: 5.157

6.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Authors:  Keiichi Kondo; Jeff Klco; Eijiro Nakamura; Mirna Lechpammer; William G Kaelin
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

7.  Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap.

Authors:  Jüri Reimand; Ruth Isserlin; Veronique Voisin; Mike Kucera; Christian Tannus-Lopes; Asha Rostamianfar; Lina Wadi; Mona Meyer; Jeff Wong; Changjiang Xu; Daniele Merico; Gary D Bader
Journal:  Nat Protoc       Date:  2019-02       Impact factor: 13.491

Review 8.  The VHL/HIF axis in clear cell renal carcinoma.

Authors:  Chuan Shen; William G Kaelin
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

9.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

10.  Model-based analysis of ChIP-Seq (MACS).

Authors:  Yong Zhang; Tao Liu; Clifford A Meyer; Jérôme Eeckhoute; David S Johnson; Bradley E Bernstein; Chad Nusbaum; Richard M Myers; Myles Brown; Wei Li; X Shirley Liu
Journal:  Genome Biol       Date:  2008-09-17       Impact factor: 13.583

View more
  9 in total

1.  USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer.

Authors:  Haibiao Xie; Jin Zhou; Xijuan Liu; Yawei Xu; Austin J Hepperla; Jeremy M Simon; Tao Wang; Hongwei Yao; Chengheng Liao; Albert S Baldwin; Kan Gong; Qing Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-29       Impact factor: 12.779

2.  OTUB1 augments hypoxia signaling via its non-canonical ubiquitination inhibition of HIF-1α during hypoxia adaptation.

Authors:  Xing Liu; Hongyan Deng; Jinhua Tang; Zixuan Wang; Chunchun Zhu; Xiaolian Cai; Fangjing Rong; Xiaoyun Chen; Xueyi Sun; Shuke Jia; Gang Ouyang; Wenhua Li; Wuhan Xiao
Journal:  Cell Death Dis       Date:  2022-06-22       Impact factor: 9.685

Review 3.  Ubiquitin-specific peptidase 37: an important cog in the oncogenic machinery of cancerous cells.

Authors:  Ajaz A Bhat; Tariq Masoodi; Ravi Chauhan; Puneet Bagga; Ravinder Reddy; Ashna Gupta; Zahoor Ahmad Sheikh; Muzafar A Macha; Mohammad Haris; Mayank Singh
Journal:  J Exp Clin Cancer Res       Date:  2021-11-10

4.  Identification of ubiquitinated substrate proteins and their gene expression patterns in lung adenocarcinoma.

Authors:  Ran Xu; Tong Lu; Jiaying Zhao; Qi Li; Jun Wang; Bo Peng; Jian Liu; Pengfei Zhang; Lidong Qu; Xiaoyan Chang; Lingqi Yao; Linyou Zhang
Journal:  Ann Transl Med       Date:  2021-11

5.  The deubiquitinase OTUD1 inhibits non-small cell lung cancer progression by deubiquitinating and stabilizing KLF4.

Authors:  Xiaoyan Ma; Liming Wang; Guifang Shi; Shuqing Sun
Journal:  Thorac Cancer       Date:  2022-01-30       Impact factor: 3.500

6.  Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective.

Authors:  Hongda Guo; Yan Li; Yaxiao Liu; Lipeng Chen; Zhengdong Gao; Lekai Zhang; Nan Zhou; Hu Guo; Benkang Shi
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

Review 7.  Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications.

Authors:  Rachel Shi; Chengheng Liao; Qing Zhang
Journal:  Cells       Date:  2021-03-19       Impact factor: 6.600

8.  USP28 facilitates pancreatic cancer progression through activation of Wnt/β-catenin pathway via stabilising FOXM1.

Authors:  Leifeng Chen; Zheng Xu; Qing Li; Qian Feng; Cihua Zheng; Yunyan Du; Rongfa Yuan; Xiaogang Peng
Journal:  Cell Death Dis       Date:  2021-09-28       Impact factor: 8.469

9.  miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37.

Authors:  Mi Seong Kim; So Hui Kim; Sei Hoon Yang; Min Seuk Kim
Journal:  Cancer Res Treat       Date:  2021-08-03       Impact factor: 4.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.